The prevention and treatment of anaemia in newborn patients made tremendous progress in the last decades. However, red-blood-cell (RBC) transfusions remain unavoidable in many neonates candidate to surgery and especially in preterm infants. In particular, anaemia occurring in neonates born at extremely low gestational age is actually severe and frequently requires transfusions. Several approaches have been explored to prevent or even to reduce the threshold and the frequency of RBC transfusions. Among these, umbilical cord blood (UCB) collection and processing to obtain RBC components for autologous or allogeneic transfusion have been extensively investigated. In this systematic review, we revised the literature concerning the use of UCB for either autologous or allogeneic transfusion purposes and we illustrated the rationale for a transfusion therapy tailored to extremely preterm neonates, based on RBC concentrates from allogeneic UCB donations.
Introduction
Severely sick preterm infants (i.e. neonates born before 37 weeks of gestation), and in particular extremely low gestational age neonates (ELGAN; i.e. neonates born before 28 weeks of gestation), inevitably necessitate blood component transfusion. Many efforts have been made to identify individualized therapeutic strategies and limit their exposure to red-blood-cells (RBCs) from adult donors. Umbilical cord blood (UCB) has been used as a source of RBCs for transfusion purpose in term and preterm neonates candidate to surgery directly after birth, or even to treat the anaemia of preterm infants. [1] . Since 1939, when Halbrecht published the first experience concerning placental blood transfusion [2], several attempts have been made to optimize the use of cells derived from UCB. Fetal blood in the placenta and umbilical vessels was initially used as a source of blood for transfusion until World War II. In some hospitals in New York, it was used until the late 1960s and, currently, its use is being reported in the literature in specific contexts like developing countries. Nevertheless, recent observations linking adult blood transfusions and poor outcome of a preterm newborns might draw new interest on this practice.
In the following sections, after a concise introduction on the anaemia of prematurity, we attempted to illustrate the rationale for using UCB instead of adult blood to transfuse preterm infants and we reviewed the literature on this topic, relatively to both autologous and allogeneic settings.
Anaemia in term and preterm neonates
Physiologically, the adaptation of the newborn to postnatal life induces in full-term neonates a transitory condition named 'physiologic anaemia of childhood' [3] . In concomitance with the switch of the synthesis from the fetal to the adult haemoglobin (Hb), the increased oxygen availability in the extra-uterine environment results in the progressive increase in tissue oxygen delivery. This causes a down-regulation of the erythropoietin (EPO) production, with a transitory suppression of erythropoiesis. The normal decline of Hb lasts until 8-12 weeks of age, when the nadir of about 11 g/dl is reached. Henceforward, the consequent decrease in tissue oxygenation again stimulates EPO production. In healthy term babies, the physiological anaemia presents without signs, and treatments are not required [3] [4] [5] . The Hb level at birth depends on the gestational age [3, 6] . Therefore, in preterm infants, the lower the gestational age, the more severe the anaemia [3, 7, 8] . Looking at haematological parameters at birth in a large series of neonates born from 22 to 40 weeks of gestation, Jopling et al. reported that for every week of gestational age advance, Hb concentration increases by 0Á21 g/dl, and haematocrit by 0Á64%, with no significant difference between males and females [6] . These circumstances partly explain why preterm infants experience a more severe anaemia than term neonates. In addition, further than being more pronounced, the Hb decline in preterm infants occurs at an earlier postnatal age (namely around 4-8 weeks) [3, 7, 8] . Particularly in ELGANs, anaemia is exacerbated by various additional physiological and non-physiological factors. First, the EPO response to anaemia in these patients is much less efficient than in term neonates [3, 7, 8] . As widely known, in a preterm baby, the main site of EPO production is still the liver, which has a threshold for hypoxia set at much lower level than the kidney. A shorter survival of fetal RBCs as compared to adult RBCs has also been reported [9] , even though more recent observations ascribe this findings to recipient-related factors more than on intrinsic fetal RBC characteristics [10, 11] . In addition, the anaemia of preterm neonates may be worsened by the deficiency of iron or other micronutrients, by the inflammatory status accompanying various infectious or non-infectious complications to whom these patients are highly exposed, and overall, by the iatrogenic blood loss due to the intensive clinical monitoring [12] . In general, the 'anaemia of prematurity' is associated with clinical findings such as pallor, poor weight gain, decreased activity, tachypnoea, tachycardia and feeding problems [3, 7, 8] .
Therapy of anaemia in premature neonates
Current therapeutic approaches are aimed at counteracting the progressive decline of Hb level and preventing the adverse effects connected with RBC transfusions. Several well-known reviews and guidelines have addressed this topic [4, 5, 13-15], which is behind the scope of the present review. The mainstays of treatment of prematurity anaemia include (1) restriction of the iatrogenic blood loss: this outcome is attainable through the use of noninvasive bilirubin monitoring and point-of-care devices for biochemistry testing, and through the caregivers' training in limiting blood sampling to the minimum required volume [12, 16] . (2) EPO administration: the early EPO administration stimulates erythropoiesis and moderates the course of anaemia: over time this results in the reduction of subsequent RBC transfusions [17] . Despite previous concerns on the association between EPO therapy and retinopathy severity, EPO in preterm neonates is currently considered safe and possibly able to decrease the risk of neurological and gut damages [18] . (3) Enteral iron supplementation and optimized nutrition [19, 20] . (4) Umbilical cord milking or delayed cord clamping: both these procedures can achieve similar amount of feto-placental blood transfusion and can be considered therefore comparable [21] . The beneficial effects of these procedures have been observed in numerous studies and have been revised in two recent metaanalyses. The first one included 15 studies and overall 738 infants: in comparison with the early clamping, delaying cord clamping for 30-120 s was associated with less need for transfusion during hospitalization, better circulatory stability, less intraventricular haemorrhage and lower risk for necrotizing enterocolitis [22] . The subsequent meta-analysis of 27 clinical trials included 2834 preterm infants: the practice to postpone the cord clamping at ≥30 s after the birth was associated with decrease of in-hospital mortality and need for transfusions, whereas the incidence of major neonatal morbidities was not affected [23] . Finally, a recent randomized trial has compared early (≤10 s) and delayed (≥60 s) clamping in 1566 preterm neonates: although no differences in the primary outcome of death or major morbidities were reported, less infant in the delayed-clamping group received subsequent RBC transfusion by 36 weeks of postmenstrual age [24] .
Transfusion therapy in preterm patients
Notwithstanding all the above-mentioned measures, RBC transfusion requirements among preterm neonates remain high, with ELGAN patients receiving transfusions much more frequently than other babies. Sacher et al. [25] reported that almost 90% of extremely low birth weight (ELBW, < 1000 g) neonates receive at least one RBC transfusion during their hospitalization. Importantly, 60% to 80% of these transfusions are given within the first 3-4 weeks of life, when the EPO effect is still barely evident [26] . Regarding the optimal Hb threshold for transfusion, a wide variation among guidelines exists [27, 28] .
According to published guidelines, neonates must be transfused with leucodepleted RBC products and, if possible, by dividing an adult RBC unit by 4 or 5 50-ml pedipacks, to limit the infectious risk exposure [29] [30] [31] . The use of blood components which are CMV-serologically negative single-donor is strongly recommended but not mandatory. Moreover, these products should be irradiated to prevent the occurrence of transfusion-associated graft versus host disease (GvHD) [29] [30] [31] . Finally, the use of fresh RBC products is advocated, to decrease the detrimental effects exerted by harmful molecules released during the storage [32].
The rationale for using umbilical blood to transfuse preterm neonates During the last weeks of gestation, various changes in the fetus provide for the transition from the relative hypoxic intrauterine environment to the oxygen-rich extra-uterine one: the antioxidant (AO) enzyme system (i.e. superoxide dismutase, glutathione peroxidase, catalase) is progressively up-regulated, and, in the meanwhile, the trans-placental passage of non-enzymatic AOs (vitamins A, E and C, trace elements, etc.) increases [33, 34] . All these processes peak at term, with labour [33] . In premature neonates, and in particular in ELGANs, the AO reserve is severely impaired and the response to the oxidative burden due to birth itself, O 2 therapy, anaemia or infections, is dramatically inadequate. The consequent oxidative stress causes the so-called 'oxygen radical disease of neonatology', including hypoxic/hemorrhagic brain damages, retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC), with long-life invalidating sequelae [34] . In turn, many of these complications worsen anaemia and further increase the transfusion requirements of these fragile patients. The repeated RBC transfusions in preterm infants, though largely unavoidable, are acknowledged risk factors for prematurity-associated diseases and constitute an independent predictor of adverse outcome [35] [36] [37] [38] . In particular, retinopathy of prematurity (ROP) and bronchopulmonary dysplasia (BPD) are the most heavily implicated [39-48], whereas recent evidence suggests a major role for severe anaemia rather than RBC transfusions in the case of necrotizing enterocolitis (NEC) [49] .
The inflammatory response and immunosuppression elicited by allogeneic blood products might constitute the connection between RBC transfusions and prematurity diseases [32] . The immune activation can be related to the unbound iron overload resulting from the post-transfusion breakdown of older RBCs [50] , to the priming of recipients' neutrophils by microvesicles [51] , and to the production of reactive species of oxygen by free iron ions, and nitric oxide depletion [52] . Importantly, all these effects have been documented in preterm infants in consequence of allogeneic RBC transfusions [46, 47, 53, 54] . Since to transfuse fresh RBC products does not seem protective in term of 90-day incidence of major neonatal morbidities or death [55] , additional factors than the storage length could be implicated. Residual leucocytes that unavoidably contaminate RBC products despite leucoreduction, as well as soluble mediators derived from leucocytes, are among the main responsible for these detrimental effects [32] . As compared with their adult counterparts, however, neutrophils, monocytes and immune lymphoid cells of fetal blood exhibit a highly tolerant phenotypes and are much lesser capable to evoke a proficient inflammatory response [56] . Moreover, soluble HLA-G molecules contained in UCB also exert an immunomodulatory function [57] ( Fig. 1) .
As a result of the adult RBC transfusions in preterm infants, a progressive decline of physiological levels of fetal Hb occurs. Normally, the switch from c-to b-chain synthesis, determining the progressive increase in adult Hb (a 2 b 2 ) at expense of fetal Hb (a2c2) production, starts around week 32 of gestation and is regulated through transcriptional repression according to the postconceptional age of the fetus [58, 59] . As a result, preterm infants continue to produce predominantly fetal Hb until the postconceptional age of 40 weeks [60] . From the functional point of view, the primary characteristic of fetal Hb as compared to adult Hb is a higher oxygen affinity, related to the low proficiency of deoxygenated fetal Hb to interact with 2,3 diphosphoglycerate (2,3-DPG), an organophosphate compound produced by erythrocytes in response to hypoxaemia. In contrast to fetal Hb, 2,3-DPG efficiently stabilizes the deoxygenated form of adult Hb, preventing it from oxygen binding [61] . Further than less effective on fetal Hb, intracellular levels of 2,3-DPG in fetal erythrocytes are also lower as compared to erythrocytes of term infants [62] . A significant association between adult Hb level and ROP has been observed in preterm neonates, so that it has been hypothesized that fetal Hb 'per se' might exert a protective role from the oxidative stress [48, 63] . In a pilot, prospective study, fetal Hb level and risk for ROP development were correlated [48] . Twenty-four infants with less than 32 weeks of gestation and 1500 g of weight were included. Infants who developed ROP had lower fetal Hb level when compared to those infants with the absence of ROP, and the correlation was also confirmed by a regression model in both unadjusted and adjusted analysis for birth weight, gestational age and total transfusion volume [48] . How fetal Hb does exert its protective effect on the ROP is largely unknown. Original studies in animals and humans receiving repeated intrauterine transfusions documented that adult Hb retains the low oxygen binding properties also in the fetus circulation [64] . The lower oxygen affinity of adult Hb does not seem to influence fetal metabolism when Hb levels are normal; nevertheless, during moderate or severe anaemia, it has been shown that cord blood samples containing higher levels of adult Hb have also a lower pH and higher base deficit [65, 66] . Notably, as compared to adult Hb, fetal Hb has a significantly greater capacity to generate nitric oxide (which plays an important role in regulating vascular tone and blood flow) [67] , is oxidatively more stable [68] and is less prone to the DNA cleavage activity [69] .
Based on all the above-mentioned considerations, UCB might be more physiological than blood from adult donors for the transfusion therapy of preterm neonates (Fig. 1) .
Review of studies on umbilical cord blood as a source for transfusion Search strategy, information sources, eligibility criteria and assessment
In order to perform a careful revision of articles addressing the use of UCB for autologous or allogeneic transfusion, we adopted a systematic search strategy on We excluded papers in which UCB was not used for transfusion purposes, communications at congresses, duplicated studies and papers not in English. M.B, C.G.V. and L.T independently controlled all references, including observational studies, case report, case series and reviews. Discrepancies were discussed and resolved together. They checked study type, population, UCB collection characteristics, RBC production if applicable, study design and outcomes. In total, 191 references were identified on May 2018. In the end, 47 papers were included and discussed in the review (Fig. 2) . In Tables 1, 2 and 3, studies from 1995 are reported illustrating case reports and case series on UCB transfusion.
Results: autologous umbilical cord blood transfusion
Several authors suggested the possibility of using cord blood as an alternative to adult blood transfusion [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] . We reported four case reports [70, 72, 74, 78] and thirteen case series [71, 73, [75] [76] [77] [79] [80] [81] [82] [83] [84] [85] [86] . Fig. 1 Factors underlying the putative protective effects of umbilical cord blood transfusions in preterm neonates. Repeated transfusions in preterm neonates constitute represent a significant risk factor for morbidity and mortality. Different factors might be involved in connecting RBC transfusions and prematurity diseases. As compared to adult Hb, fetal Hb displays greater capacity to generate nitric oxide, is more stable in an oxidative environment and is more resistant to the DNA cleavage activity. Residual leucocytes in fetal blood products exhibit a tolerant phenotype and umbilical blood also contains soluble HLA-G molecules, which exert an immunomodulatory function. Future studies are appropriate, further investigating the different nature and composition of microvesicles in adult and cord blood, as well as pro-inflammatory and immunologic effects induced by their transfusion in preterm neonates.
Transfusions were performed because of neonatal anaemia in seven cases [70-72, 79, 80, 85, 86] , surgical indications such as congenital malformations [73, 77, 78, 82] and cardiac surgeries [74, 81, 83, 84] in eight cases. Two papers reported an experience in both anaemic and surgical patients [75, 76] . Cord blood was collected in preterm [70-72, 78-80, 85, 86] , term neonates [74, 81, 84] as well as in both [73, 75, 77] . The rate of transfusion is quite wide, ranging from 2Á3 to 100% of enrolled patients with a great variability of the median volume of cord blood collected (Table 1) .
Collection and dosing of autologous UCB
The studies on autologous UCB transfusion suggested that the collection of UCB is not feasible in all deliveries: for example, Jansen et al. found that among premature infants (24-36 weeks), UCB collection was feasible only in 111 out of 179 deliveries (62%), due to fetal, placental or maternal clinical complications [79] . In addition, as above mentioned, a wide variation of UCB unit volume is observed, ranging from less than 15 ml [79, 80] to 150 ml [82] ; moreover, the UCB volume is directly proportional to the weight at birth [70] . This finding parallels what is observed in UCB collection for transplantation, where the main goal is to achieve a high number of total nucleated cells [80] . Obviously, UCB units with larger volume may guarantee an adequate transfusion dose, which is generally 20 ml/Kg plus the volume for the infusion set. The low collected volume appears as the main limit of the UCB autologous transfusion strategy: starting a program to use UCB units for transfusion should take account for criteria to identify neonates with a high probability of collecting units with an adequate volume. Since autologous UCB mainly covers one single transfusion dose, it appears suitable for full-term infants with prenatal diagnosis of diseases requiring surgical interventions soon after the birth [73, 75, 77, 78, [81] [82] [83] [84] . For example, in cardiac surgery, Chasovskyi et al. reported that UCB collected at delivery could be used for autologous transfusion in all patients with a prenatal diagnosis of arterial transposition undergoing surgery [83] or for the priming of the cardio-vascular bypass [81, 84] .
Efficacy of autologous UCB transfusion
In studies enrolling only term babies, additional allogeneic transfusions were not necessary [74, 78] or they were performed only in a few of patients, from 4Á7% [81] to 12Á5% [84] . Conversely, in case of preterm neonates, 27% to 64% of patients did [73, 75, 77] . When these data were analysed according to the birth weight, additional allogeneic transfusion after surgery occurred in 60% of preterm infants with birth weight between 1000 and 2500 g [76] . Similarly, in preterm infants, autologous UCB cannot cover entirely the requirements of repeated transfusions necessary in case of anaemia. Brune showed that the risk of allogeneic transfusion is about 70%, with the highest probability for neonates weighing at birth less than 1000 g [75, 76] . Similar conclusions were achieved by Jansen et al. [79] and Khodabux et al. [80] , showing that 59% and 50% of patients, respectively, received additional allogeneic transfusion after UCB. However, since these studies date more than 10 years ago, we cannot exclude that the strategies currently adopted to limit the iatrogenic blood loss might mitigate the need for allogeneic transfusions. In terms of Hb increment, Eichler et al. and Brune et al. showed no differences between autologous and allogeneic transfusions, while the Hb decreases per day after transfusion was slightly higher in the UCB group [71, 76] . In terms of adverse events, no coagulopathy, haemolysis or post-transfusion bacterial infection was reported in autologous UCB. UCB units may be considered a safe blood component provided that microbial testing has been carried out [70, [75] [76] [77] 86] .
In conclusion, autologous UCB can cover the perioperative transfusion supplies in full-term neonates Results: allogeneic umbilical cord blood transfusion UCB has been a valuable and well-recognized source of hematopoietic stem cells for transplantation since its first use in 1988 [87] . Due to the high concentration of haemoglobin, it may be used also for transfusion purposes in different contexts [88, 89] . In Table 2 , we illustrated published case series on allogeneic UCB use in adults and neonate patients with anaemia. Bhattacharya [90] [91] [92] [93] [94] [95] [96] [97] [98] and Hassall [99, 100] reported data about UCB transfusion performed in low-income countries in several different conditions such as thalassemia [90] [91] [92] , autoimmune disease [90, 91, 94] , cancer [90] , renal failure [90] , diabetes [98] , infectious diseases [93, 95, 97, 99] and anaemia in adult [90, 96] and childhood [100] . Our group reported an experience in extremely low birth weight (ELBW) neonates in a tertiary-care hospital [101] . In all studies, transfusions were performed using whole cord blood, except in two papers published by Hassall [100] and Bianchi [101] where RBC concentrates were obtained from cord blood fractionation.
Clinical efficacy of allogeneic cord blood RBC transfusions
In Hassall's paper, 55 children received 74 RBC concentrate transfusions with a dose ranging from 10 to 20 ml/Kg, according to the level of malnutrition, defined as a weightfor-height Z score less than -3 in children older than 3 months. Children with severe malnutrition received a maximum permitted volume of 10 ml/kg while children without severe acute malnutrition received a maximum volume of 20 ml/kg [100] . After transfusion, the haemoglobin concentration rose by 26 g/l after 24 h and by 50 g/l after 28 days. No serious adverse events or adverse events certainly attributable to cord blood transfusion were reported. This single-institution experience showed that cord blood transfusion is feasible and safe and it might be the best choice in settings where the demand for lowvolume units is high and supplies of adult blood units are low [100] . Bianchi et al. reported an experience in a selected population of ELBW neonates in the first 4 weeks of life. For the study design, patients received cord blood or adult donor RBCs at same doses (20 ml/Kg) according to the availability of ABO and Rh matched cord blood units [101]. The preterm infants receiving cord blood RBCs or adult RBCs had a similar sex and age distribution, gestational age, birth weight, Apgar scores, haematocrit and haemoglobin levels at birth; the triggers for transfusion were also similar between groups. This study clearly showed that adult and cord blood RBC transfusions produced a similar raise of the haematocrit (43Á5 -5Á1 and 44Á5 -5Á3, in cord and adult group, respectively). Moreover, both groups received a similar mean number of transfusions in the first 28 days of life, at comparable time intervals between transfusions. No acute transfusion reactions and adverse events related to transfusions were recorded among patients of both groups, including fever, haemolysis, allergic reactions or transfusion-related acute lung injury (TRALI). Among delayed adverse events, no transfusion-associated GvHD or CMV infections were observed. Notably, at a retrospectively analysis of the ROP incidence among patients included this study, it has been reported that all prematures receiving adult RBCs developed ROP, while 2 of 6 patients in the cord blood RBC group did not. Most severe stage of ROP was observed in four heavily transfused prematures: three of them were transfused only or mainly with adult RBCs [63] .
Technical aspects
Using UCB for transfusion purposes, one should consider various peculiar issues connected with the low volume, fetal erythrocytes fragility, eventual presence of clots and possible contamination. In Table 3 , we show main studies illustrating fractionation and production of RBC concentrates as well as quality controls [100] [101] [102] [103] [104] . Fractionation of whole UCB allows to obtain RBC concentrates with similar baseline characteristics as units from adult donors, although the storage of cord RBC units was associated with increased supernatant potassium, higher rate of haemolysis and decreased intracellular ATP. These data were also confirmed in a study evaluating the storage of whole UCB [105] . Moreover, a more pronounced lactate increase and pH and glucose decrease were reported [100] [101] [102] [103] [104] . Two experiences on UCB fractionation and short-term storage (14 days) carried out at our institution in 2012 [106] and in 2015 (Bianchi M. and Teofili L.,), confirmed these findings. Fractionated units seem also to have a reduced shelf life when compared with unfractionated ones [104] . Based on the quality controls performed, a different expiration date should be defined for cord blood RBCs, shorter than for adult RBCs. This should also allow blood component irradiation if required. Notwithstanding fractionated units seems to have a reduced shelf life, in the setting of paediatric transfusion, this may guarantee units with higher haemoglobin concentration and a lower total volume. Finally, haematocrit, red cell ATP and red cell shape were maintained during storage. As expected, red cell 2,3-diphosphoglycerate declined and potassium levels rose significantly but were not different than levels reported for adult cells similarly preserved. UCB units have a major rate of microbial contamination when compared to blood collected from adult donors. Microbial contamination in cord blood presents a highly variable rate (0-8Á6%) [70-75, 77, 78, 80, 84] and is more frequent in vaginal delivery or when the collection staff is not well-trained [107] . In the autologous setting, Surbek et al. suggested that some clinical conditions at the time of the delivery, such as chorioamnionitis, should be regarded as a contraindication for autologous cord blood collection because associated to the high incidence of cord blood contamination [72] . In this paper, Bacteroides spp., Staphylococcus spp. and Propionibacterium spp. accounting for 13Á7% of all positive results were the most common microbial contaminants [72] . Indeed, all UCB units for transplantation, transfusion (whole blood and RBC) and topic purposes (i.e. cord blood platelet gel, CBPG) must undergo bacterial and fungi cultures before the release for clinical use according to international regulations and standards. This causes a delay in the release of the cord RBC unit, estimated in 5-6 days after collection, and it is generally associated with a higher mean storage time at the time of transfusion of cord RBC (7 days, range 3Á2-10), when compared to adult RBC units (3Á5 days, range 1-6) [101] . Application of alternative screening methods for microbial species such as molecular techniques for pathogen detection and identification could be explored to identify more rapid diagnostic tests [108] .
Clots represent an additional problem for the utilization of UCB. At the time of collection, gentle mixing units may avoid clot formation; moreover, using set with primary and additional anticoagulant bags can help to avoid clots formation in the collection bag as well as in the tubes. Possibly, unfractionated UCB units should undergo filtration before infusion to remove clots, which are not visually detectable [109] .
These various drawbacks did not translate into clinically evident adverse events in recipients, even though severely ill neonates [70, 75-77, 86, 100, 101] . Finally, cord blood may be contaminated by maternal blood cells. The contamination can occur relatively frequently, estimated at 2-20% of collected samples, but its rate is very small (10 -4 to 10 -5 fetal nucleated cells) and can be detected only by molecular biology techniques [110] .
Future perspectives
Numerous previous experiences on collection, fractionation and transfusion of cord RBCs have shown that this practice is feasible and safe and can prevent or reduce the exposure to allogenic adult RBCs when used for surgery transfusion needs of term infants. Noticeably, preliminary clinical evidence suggests that transfusing UCB might limit the occurrence of ROP in preterm neonates. This hypothesis deserves to be explored in prospective clinical trials in these high-risk patients randomized to receive adult or UCB products. Biomarkers of oxidative stress after different types of products should be investigated, exploiting those assays which at present are mainly confined to the basic research field [111] . Furthermore, the use of the near-infrared spectroscopy could help to detect the different oxygen delivery and consumption in tissues for the two transfusion strategies [112] . In parallel, a program to convert to RBC concentrates those units which are not suitable for stem cell banking should be designed. In Italy, every year almost 15 000 cord blood units are collected but less than 10% are suitable for allogeneic transplantation (available at www.centronazionalesangue.it). The main cause of exclusion from banking is the low total nucleated cell count. However, most of the discharged units have an adequate volume for subsequent fractionation in blood components such as RBCs and maybe indeed used for transfusion purposes. According to our previous experience, we can anticipate that about three cord blood RBC units can cover the transfusion need of most ELGAN patients during the first month of life [101, 113] .This reconversion may also have a significant impact in terms of increase and requalification of the activities of cord blood banks.
From an economic point of view, the production of UCB RBCs may apparently appear more expensive. The production of UCB RBC needs a fractionation kit with filter for leucoreduction; nevertheless, splitting an adult RBC unit needs a ped-pack kit too. Moreover, the ped-pack policy is not universally adopted, and in most institutions RBC units which have been split may expire before use. Finally, the collection of cord blood from one individual involves not only technical and medical issues but also ethical issues. Families who decide to donate cord blood are making a choice to do something that may potentially benefit unknown recipients. Indeed, we hope that in a very close future, this might consist in donating UCB units for transplantation as well as for transfusion. 
